Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its 86-year history. The Detroit insurer, the state’s most dominant with a 63% ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for obesity and lifestyle drugs ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Participants taking Zepbound lost more weight and more inches off their waistline than those taking Wegovy. People taking Zepbound lost nearly 50% more weight than those on Wegovy. Now ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

Eli Lilly and Company’s LLY Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s NVO Wegovy in a 72-week head-to-head trial. What Happened: Participants treated with ...